AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis

Conditions: Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV Interventions: Drug: AB-101; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Rituximab Sponsors: Artiva Biotherapeutics, Inc. Recruiting

Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials